03 jul: Europa luk: Hæderlige stigninger over alt
04 jul: USA/aktier: Fabriksordrer og bilsalget løftede markedet
03-07-2012 21:09:00

UPDATE: FDA Approves OraSure's Over-The-Counter Home HIV Test

Relateret indhold

--FDA approves first HIV test to be sold in retail stores

--Test will be available in October

--Home test appears to be not as accurate as tests by health professionals

(Adds company comments on test availability, pricing, in the third and fourth paragraphs.)

By Jennifer Corbett Dooren

WASHINGTON--The Food and Drug Administration Tuesday approved a home HIV test that will be sold in retail stores so people wouldn't have to go to a health facility to learn if they have the virus.

The test, made by OraSure Technologies Inc. (OSUR), has been available to health-care professionals. The test, called the OraQuick In-Home HIV test, uses a mouth swab to collect saliva. The swab is then inserted into a test tube where results are made available within a 20-to-40 minute time frame.

Company officials said the test will be available in October and sold at more than 30,000 retailers such as Wal-Mart Stores Inc. (WMT) and large grocery and drug-store chains including CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and Walgreen Co. (WAG). The test will also be sold online.

OraSure said a price hasn't been established but it will be slightly higher than the $17.50 currently paid by health-care professionals, to fund additional labeling costs and a customer-support center.

The FDA said a positive result needs to be confirmed with a follow-up test in a health-care facility. The agency also said negative readings don't necessarily mean people aren't infected with HIV because the test might not be able to pick up infections within three months before testing.

Still, the agency said the test has the potential to identify large numbers of previously undetected HIV infections, especially if used by people unlikely to use standard screening methods.

About 1.2 million people in the U.S. are infected with HIV, and about 50,000 infections are diagnosed each year, a level that has been stable for a decade. Federal health officials have estimated that 20% of people with HIV don't realize they are infected and risk spreading the virus, which causes AIDS.

"Knowing your status is an important factor in the effort to prevent the spread of HIV," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research. "The availability of a home-use HIV test kit provides another option for individuals to get tested so that they can seek medical care, if appropriate."

However, there is one concern about the home test: Clinical testing has showed it doesn't appear to be as accurate as tests conducted by health professionals.

One measure of the test's accuracy in the home setting showed it had a sensitivity rate of 92%. The FDA said this means there would be one false negative test result for every 12 tests taken in HIV-infected individuals.

The FDA said one false positive result would be expected out of every 5,000 test results taken by uninfected individuals.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com.

(END) Dow Jones Newswires

July 03, 2012 15:09 ET (19:09 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Dongs solgte olieforretning tager fokus - NY

24-05-2017 08:18:00
Dong stryger i fokus onsdag morgen med en aftale om salg af sin olie- og gasforretning inden den forlængede weekend. Forretningsdelen blev sat til salg i efteråret, og køberen er Ineos, der tidligere har været rygtet som mulig køber.Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2017-forventningerne. Dong-aktien steg tirsdag 0,6 pct. til 281,80 kr.C20 Cap-indekset sluttede tirsdag med en sti..

KORR: Topdanmark Q1: Gode resultater giver plads til opjustering

23-05-2017 16:10:36
(Korr: Periodens resultat i Q1 17 er rettet i tabel)Forsikringskoncernen Topdanmark kom ud af det første kvartal i år med et nettooverskud på 415 mio. kr., hvilket var bedre end analytikernes forventninger, og selskabet opjusterer forventningerne til 2017.Ifølge et estimat, som Ritzau Estimates har indsamlet, havde analytikerne ventet et overskud på 318 mio. kr. i kvartalet.I samme periode af 2016..

Gigantisk vindprojekt går efter 100 pct. PTC trods 2021/23-afslutning

23-05-2017 14:04:08
Et selskab under Denver-baserede The Anschutz Corporation, som den amerikanske multimilliardær Philip Anschutz står bag, går efter at få tildelt PTC-støtte til den fulde sats, selv om halvdelen af det gigantiske vindprojekt på 3000 megawatt først planlægges opført i 2021-2023.Det bekræfter udviklingsselskabet bag projektet, Power Company of Wyoming (PCW), over for Ritzau Finans.Hos Sydbank betegne..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Gigantisk vindprojekt går efter 100 pct. PTC trods 2021/23-afslutning
2
Trump holder fingrene fra medicinpriserne i USA trods kritik - citat
3
Zealand: Partner ser mulighed for kunstig bugspytkirtel i 2020/21
4
Aktier/tendens: Dongs solgte olieforretning tager fokus - NY
5
Genmab: Darzalex-salget falder lidt men holder stadig højt niveau

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. maj 2017 11:54:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB3 - 2017-05-24 11:54:32 - 2017-05-24 11:54:32 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x